The Journal of Pharmacology and Experimental Therapeutics (JPET) has a long history of excellent Editors, Editorial Advisory Board members, and Reviewers who have served the loyal readers and authors. I feel privileged to have served all stakeholders in JPET for the past 6 years.
One of my primary goals as Editor was to increase the quality of the manuscripts published in JPET. As such, that means weaker submissions must be identified and rejected, an unpopular task at best. Nevertheless, the JPET acceptance rate decreased from a historical average of 45 to 50% to approximately 37% in 2008, a rate that suggests greater selection and, in turn, greater quality of publications. With that said, I have also held the philosophy that authors should have an opportunity to revise and re-submit their manuscripts.
JPET historically has published more papers in the fields of neuropharmacology and cardiovascular pharmacology than any other area, and this trend remains true. However, growth in several other areas has unfolded; for example, there has been a marked increase in the number of gastrointestinal pharmacology papers and submissions focused on immunopharmacology, inflammation, and pulmonary pharmacology. These emerging areas of interest are a positive change for JPET, and I am pleased that JPET can raise the visibility of these important works in the scientific literature.
In closing, I thank the reviewers, Editorial Advisory Board, Associate Editors, Assistant Editor Dr. Craig Beeson, Managing Editor Jill Filler, Editorial Coordinator David Williams, and Editorial Assistant Cassie Wood for their dedication and hard work. I leave the journal in the excellent hands of Dr. Michael Jarvis.
- © 2009 by The American Society for Pharmacology and Experimental Therapeutics